Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

Building the future “Solvay Pharmaceuticals” 14 Strategy Solvay Pharmaceuticals announces new performance objectives In July 2005, Solvay Pharmaceuticals completed its acquisition of Fournier Pharma. In October it presented the new combined performance objectives for the future “Solvay Pharmaceuticals” by 2010: REBIT/sales in excess of 20% Annual sales growth above 7% Improving effi ciency by EUR 300 million a year. We are already on the road to achieving these objectives. Solvay Global Annual Report 2005
Key fi gures [EUR million] Pharmaceuticals Sector 2003 2004 2005 Sales 1 832 1 745 2 270 REBIT 243 236 302 Depreciation 59 65 87 Capital expenditures 153 150 1 346 R&D 284 294 351 Headcount [1] 7 530 7 988 10 004 Sales breakdown 2005: EUR 2 270 million [1] Full-time equivalents at January 1 of the following year. R&D expenditure 2005: EUR 351 million By Therapeutic fi eld Cardiometabolics 19 % Neuroscience 16 % Flu vaccines 6 % Pancreatic enzymes 7 % Gastroenterology 18 % By geographic area Hormone Therapy for Men and Women 23 % Others 11 % g Europe 37 % European Union (25) 8 % Other European countries g Asia-Pacifi c g The Americas 43 % Nafta 2 % Mercosur g Rest of the world By therapeutic fi eld Cardiometabolics 27 % Neuroscience 33 % Flu vaccines 4 % Pancreatic enzymes 7 % Gastroenterology 5 % Hormone Therapy for Men and Women 24 % 23 % 45 % 5 % 11 % 18 % 19 % 6 % 7 % 24 % 27 2 % 7 % 4% 3 % 7 % 33 % 16 % 45 % Werner Cautreels Solvay Pharmaceuticals faces fundamental changes Various signifi cant and simultaneous changes in the pharmaceuticals environment have led to adaptations within our own business. Among these changes we would mention: – unmet medical needs; – risk/benefi t ratios and safety and compliance requirements that are becoming important criteria in gaining approvals; – signifi cantly rising costs of development. Post-registration clinical work and the need to police safe and effective product use all add to the overall development costs. These are requiring companies to redefi ne their methods of working and their development plans to get their molecules registered. 15 Solvay Global Annual Report 2005 Pharmaceuticals
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17: Specialities Solvay Specialties fro
Page 21 and 22: Cardiometabolic Cardiovascular dise
Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70:
Notes to the fi nancial statements
Page 71 and 72:
(2) Financial data by region These
Page 73 and 74:
and the estimated fi nancial conseq
Page 75 and 76:
The deferred taxes recorded in the
Page 77 and 78:
2005 Millions EUR Acquisitions Disp
Page 79 and 80:
Neopharma On January 19, 2005 the S
Page 81 and 82:
(around 300 persons) with a view to
Page 83 and 84:
In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?